This process yields a product with a high level of purity and consistent product characteristics including glycoforms and biological activity. The biological activity of choriogonadotropin alfa is determined using the seminal vesicle weight gain test in male rats described in the "Chorionic Gonadotrophins" monograph of the European Pharmacopoeia.
The pH of the solution is 6. The physicochemical, immunological, and biological activities of recombinant hCG are comparable to those of placental and human pregnancy urine-derived hCG. Choriogonadotropin alfa stimulates late follicular maturation and resumption of oocyte meiosis, and initiates rupture of the pre-ovulatory ovarian follicle.
In pregnancy, hCG, secreted by the placenta, maintains the viability of the corpus luteum to provide the continued secretion of estrogen and progesterone necessary to support the first trimester of pregnancy. The volume of the central compartment is 3. One-tenth of the dose is excreted in the urine. No drug-drug interaction studies have been conducted. The study was conducted in 20 U. The primary efficacy parameter in this single-cycle study was the number of oocytes retrieved.
This double-blinded study was conducted in nine centers in Europe and Israel. The primary efficacy parameter in this single-cycle study was the number of oocytes retrieved per patient. The primary efficacy parameter in this single-cycle study was the patient ovulation rate.
The risks of gonadoptropin treatment should be considered for women with risk factors of thromboembolic events such as prior medical or family history. Careful monitoring of ovarian response can further minimize the risk of overstimulation.
If the ovaries are abnormally enlarged on the last day of FSH therapy, choriogonadotropin alfa should not be administered in this course of therapy. This will reduce the risk of development of Ovarian Hyperstimulation Syndrome. OHSS is a medical event distinct from uncomplicated ovarian enlargement. Severe OHSS may progress rapidly within 24 hours to several days to become a serious medical event.
It is characterized by an apparent dramatic increase in vascular permeability which can result in a rapid accumulation of fluid in the peritoneal cavity, thorax, and potentially, the pericardium.
The early warning signs of development of OHSS are severe pelvic pain, nausea, vomiting, and weight gain. The following symptomatology has been seen with cases of OHSS: abdominal pain, abdominal distension, gastrointestinal symptoms including nausea, vomiting and diarrhea, severe ovarian enlargement, weight gain, dyspnea, and oliguria. Clinical evaluation may reveal hypovolemia, hemoconcentration, electrolyte imbalances, ascites, hemoperitoneum, pleural effusions, hydrothorax, acute pulmonary distress, and thromboembolic events see " Pulmonary and Vascular Complications ".
Transient liver function test abnormalities suggestive of hepatic dysfunction, which may be accompanied by morphologic changes on liver biopsy, have been reported in association with Ovarian Hyperstimulation Syndrome OHSS. OHSS occurred in 4 of 1.
OHSS occurred in 8 of 89 9. OHSS may be more severe and more protracted if pregnancy occurs. OHSS develops rapidly; therefore, patients should be followed for at least two weeks after hCG administration. Most often, OHSS occurs after treatment has been discontinued and reaches its maximum at about seven to ten days following treatment. Usually, OHSS resolves spontaneously with the onset of menses. If severe OHSS occurs, treatment with gonadotropins must be stopped and the patient should be hospitalized.
A physician experienced in the management of this syndrome, or who is experienced in the management of fluid and electrolyte imbalances should be consulted. In ART, the risk of multiple births correlates to the number of embryos transferred. Multiple births occurred in 17 of 55 live deliveries In the ovulation induction clinical trial, 2 of 15 live deliveries The patient should be advised of the potential risk of multiple births before starting treatment.
As with other hCG products, a potential for the occurrence of arterial thromboembolism exists. The bigger the follicle, the better it is for the IVF process.
For most IVF treatments, a follicle that is around 15mmmm micrometers large is most likely to produce a viable egg. Skip to content Lifehacks. May 2, Joe Ford. Table of Contents. I had my trigger shot Thursday night and my iui Saturday, I tested yesterday to see if i would still show a line, which it did. Todays line was the same, not really much lighter.
Im wondering if there is a chance it could actually be my first bfp, but I really think that 7dpiui is too early for that. Myt dose was , I would love anyones input. Thanks ladies, today there is still a faint line.
Today is 10 days past trigger, or I guess 9. Pretty sure its getting lighter but its still there, Hopefully it doesnt go away and it starts to get darker. We strive to provide you with a high quality community experience. If you feel a message or content violates these standards and would like to request its removal please submit the following information and our moderating team will respond shortly.
The educational health content on What To Expect is reviewed by our medical review board and team of experts to be up-to-date and in line with the latest evidence-based medical information and accepted health guidelines, including the medically reviewed What to Expect books by Heidi Murkoff.
This educational content is not medical or diagnostic advice. Use of this site is subject to our terms of use and privacy policy. Registry Builder New. Posting as. Fertility Treatments. Community Guidelines Community Glossary. The views expressed in community are solely the opinions of participants, and do not reflect those of What to Expect.
Learn more about our guidelines Just so you know, What to Expect may make commissions on shopping links on this page. This discussion is archived and locked for posting.
Archived discussions are usually a bit older and not as active as other community content.
0コメント